Donor lymphocyte infusions: the long and winding road: how should it be traveled?
about
Immunotherapy of childhood cancer: from biologic understanding to clinical application.Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignanciesNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioIntroduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Postnatal donor lymphocytes enhance prenatally-created chimerism at the risk of graft-versus-host disease.Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions.Relapse after allogeneic hematopoietic cell therapy.Immunotherapy for pediatric leukemia.Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Second hematopoietic stem cell transplantation in myeloid malignanciesLysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.Haploidentical transplantation for leukemia.Suicide gene therapy for graft-versus-host disease.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Clinical management of patients receiving cell-based immunoregulatory therapy.New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantationDetecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate.CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft.Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma.iNKT cell activation plus T-cell transfer establishes complete chimerism in a murine sublethal bone marrow transplant model.Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation
P2860
Q33752982-91C8E131-7B6C-4FE7-93A2-3CC8AC586495Q33795160-07FE7937-18A4-48B3-A272-3AC0742BE15DQ34202277-D0672DA1-0E30-4578-B65E-9EB64562661AQ34378623-81151028-0F03-4F3F-AEF6-EBD086AB6559Q35100974-EB3C54B9-93AF-41A2-842B-E90F164CF90FQ35826497-623A8279-0CBE-4070-B8E5-93195012A1BAQ36375715-14240DC9-80C0-4CC2-BB74-ACC79702F9F6Q36799799-F83C1533-937E-4D1C-B2F2-CB60EDB7B984Q36968163-AC9C582D-F53C-4D96-AD84-AD346BCA2567Q37323038-FBD1C46E-1DAA-44DA-A5DB-78E1DE8AB2AAQ37349835-89DE1C0D-B995-4054-B12D-D452B839BA2DQ37362983-2C70BC84-B915-4D76-88C7-F0B43F94FF2DQ37370051-48417F0E-2043-4FC5-B0E3-A2B5BC9260E9Q37390239-19DA1F2A-CFE2-49AC-85EE-1259FAE80F92Q37401234-F96047A4-3D3C-42E8-B8D1-36C9CA964494Q37636670-E434C59F-A1DA-45EA-9833-791CCFEE47F6Q37770075-14057E1E-D584-4BD7-81C8-E32C531D14CEQ37773293-DD3E24CB-60BE-4383-8E53-F68BF653A172Q37905034-EDAF5032-5F88-420A-9846-B327BC8CD251Q38197075-5C0FCE43-3743-4B31-9F84-0069F3C4C04CQ38201742-59255899-B593-4140-8E0A-C384359821B9Q38643400-3A5E78E3-481E-4D0A-9352-2DC3C6F81387Q41273685-169832EC-8B7D-44C5-A88C-BCDD14560037Q41275812-65AF18A4-2ABB-49B5-B2F4-52E50A3A92B4Q41279994-9DB6C753-B7C1-485C-ACE8-101523D0C30CQ41900749-F9C0BB57-9582-49F5-8569-89744F8E6CB8Q42117471-98A383E1-EBA5-4A43-978A-0909CDAF0421Q42432554-50CBFDCA-AA69-4A96-ACCA-7201DBE9336AQ46411211-AC7F3D49-946F-4BF6-A4A7-DFE8902A7737Q47793288-DA5184C1-296A-4515-89BD-9A9D6DDDF6CAQ48306919-1A70BB27-CE46-4AEE-96DC-DFF4F4E7E25FQ48313602-45EB0C93-BE0C-432D-A441-8337AEF607E5Q58561116-8A8EF336-5A77-4103-8D60-945246E93B46
P2860
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@en
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@nl
type
label
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@en
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@nl
prefLabel
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@en
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@nl
P2860
P356
P1476
Donor lymphocyte infusions: the long and winding road: how should it be traveled?
@en
P2093
H M Lazarus
P2860
P2888
P304
P356
10.1038/BMT.2008.259
P407
P577
2008-08-18T00:00:00Z
P6179
1025625822